Alkermes (ALKS) News Today $26.97 -0.74 (-2.67%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$26.96 0.00 (-0.02%) As of 09/12/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why Is Alkermes Down Today?Toggle Visibility of Why Is Alkermes Down Today?Alkermes plc (NASDAQ: ALKS) shares are trading lower today amid a mix of leadership changes and varied analyst outlooks. Investors are weighing the impact of a new CFO appointment, fresh analyst ratings, and ongoing research initiatives on the company’s future performance. Positive Sentiment: Alkermes has named Joshua Reed as its new Chief Financial Officer, effective September 15, 2025, promoting him to oversee the company’s financial strategy and reporting. Alkermes Appoints Joshua Reed as Chief Financial Officer Positive Sentiment: Brokerages have assigned Alkermes a consensus “Moderate Buy” rating, reflecting bullish expectations among analysts. Alkermes plc Given Consensus Rating of "Moderate Buy" by Brokerages Positive Sentiment: JPMorgan Chase & Co. raised its price target on ALKS from $34.00 to $35.00, maintaining a neutral rating but signaling modest upside. Alkermes Price Target Raised to $35.00 Positive Sentiment: JPMorgan analysts forecast strong price appreciation for ALKS stock, underpinning expectations of future growth. JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Alkermes Stock Neutral Sentiment: HC Wainwright reiterated its “neutral” rating on ALKS with a $46.00 price objective, indicating a balanced risk/reward outlook. Alkermes' Neutral Rating Reiterated at HC Wainwright Neutral Sentiment: Alkermes launched its 8th annual Pathways Research Awards Program, offering competitive grants up to $100,000 for studies in areas including sleep and circadian disturbances associated with bipolar I disorder and schizophrenia. Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program Posted 1+ days agoAI Generated. May Contain Errors. ALKS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Acadian Asset Management LLC Has $29.10 Million Position in Alkermes plc $ALKSSeptember 13 at 5:36 AM | marketbeat.comBaird Financial Group Inc. Purchases New Shares in Alkermes plc $ALKSSeptember 13 at 3:13 AM | marketbeat.comAlkermes names Joshua Reed as CFOSeptember 12 at 12:44 PM | msn.comAlkermes Appoints Joshua Reed as New CFOSeptember 12 at 9:31 AM | tipranks.comAlkermes Appoints Joshua Reed as Chief Financial OfficerSeptember 12 at 9:00 AM | prnewswire.comFred Alger Management LLC Takes $1.24 Million Position in Alkermes plc $ALKSSeptember 12 at 5:20 AM | marketbeat.comAQR Capital Management LLC Sells 279,276 Shares of Alkermes plc $ALKSSeptember 12 at 3:53 AM | marketbeat.comAlkermes plc (NASDAQ:ALKS) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 12 at 3:01 AM | americanbankingnews.comAlkermes (NASDAQ:ALKS) Price Target Raised to $35.00September 11 at 4:21 PM | marketbeat.comAlkermes plc: Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards ProgramSeptember 11 at 9:20 AM | finanznachrichten.deAlkermes' (ALKS) Neutral Rating Reiterated at HC WainwrightSeptember 11 at 8:14 AM | marketbeat.comAlkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® ProgramSeptember 11 at 7:00 AM | prnewswire.comAlkermes' (ALKS) "Neutral" Rating Reiterated at HC WainwrightSeptember 11 at 2:45 AM | americanbankingnews.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for Alkermes (NASDAQ:ALKS) StockSeptember 11 at 2:13 AM | americanbankingnews.comAlkermes Target of Unusually High Options Trading (NASDAQ:ALKS)September 10 at 4:53 PM | marketbeat.comAlkermes (NASDAQ:ALKS) Hits New 12-Month Low - What's Next?September 10 at 11:42 AM | marketbeat.comAlkermes Sees Unusually High Options Volume (NASDAQ:ALKS)September 10 at 2:43 AM | americanbankingnews.comAlkermes price target lowered to $43 from $45 at NeedhamSeptember 10 at 2:27 AM | msn.comAlkermes price target raised to $35 from $34 at JPMorganSeptember 10 at 2:27 AM | msn.comAlkermes narcolepsy type 1 data largely as expected, says MizuhoSeptember 8, 2025 | msn.comAlkermes narcolepsy data ‘solid,’ about as expected, says LeerinkSeptember 8, 2025 | msn.comAlkermes Plc (ALKS) World Sleep Congress 2025 (Transcript)September 8, 2025 | seekingalpha.comAlkermes plc (ALKS) World Sleep Congress 2025September 8, 2025 | seekingalpha.comAlkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025September 8, 2025 | prnewswire.comAlkermes (NASDAQ:ALKS) Upgraded at Wells Fargo & CompanySeptember 6, 2025 | marketbeat.comAlkermes (NASDAQ:ALKS) Trading 7.2% Higher - Should You Buy?September 5, 2025 | marketbeat.comCanada Pension Plan Investment Board Purchases 9,900 Shares of Alkermes plc $ALKSSeptember 5, 2025 | marketbeat.comAlkermes (NASDAQ:ALKS) Stock Rating Upgraded by Wells Fargo & CompanySeptember 5, 2025 | americanbankingnews.comWells Fargo Initiates a Buy Rating on Alkermes (ALKS)September 4, 2025 | theglobeandmail.comMPM Bioimpact LLC Acquires Shares of 337,603 Alkermes plc $ALKSSeptember 4, 2025 | marketbeat.comPalo Alto Investors LP Decreases Holdings in Alkermes plc $ALKSSeptember 4, 2025 | marketbeat.comBaker BROS. Advisors LP Has $148.04 Million Stake in Alkermes plc $ALKSSeptember 4, 2025 | marketbeat.comVident Advisory LLC Reduces Holdings in Alkermes plc $ALKSSeptember 4, 2025 | marketbeat.com5ALKS : Deep Dive Into Alkermes Stock: Analyst Perspectives (7 Ratings)September 4, 2025 | benzinga.comWells Fargo Initiates Coverage of Alkermes (ALKS) with Overweight RecommendationSeptember 4, 2025 | msn.comAlkermes initiated with an Overweight at Wells FargoSeptember 3, 2025 | msn.comPDT Partners LLC Buys 27,436 Shares of Alkermes plc $ALKSSeptember 3, 2025 | marketbeat.comAlkermes plc (ALKS) Completes Enrollment in Key Narcolepsy Trial, Data Due Q3 2025September 2, 2025 | finance.yahoo.comDAFNA Capital Management LLC Has $3.11 Million Stake in Alkermes plc $ALKSSeptember 1, 2025 | marketbeat.comDriehaus Capital Management LLC Makes New $26.18 Million Investment in Alkermes plc $ALKSSeptember 1, 2025 | marketbeat.comRafferty Asset Management LLC Decreases Stake in Alkermes plc $ALKSAugust 31, 2025 | marketbeat.comAlkermes plc $ALKS Stake Boosted by Hsbc Holdings PLCAugust 29, 2025 | marketbeat.comNorthern Trust Corp Sells 35,242 Shares of Alkermes plc $ALKSAugust 29, 2025 | marketbeat.comThose who invested in Alkermes (NASDAQ:ALKS) five years ago are up 79%August 28, 2025 | uk.finance.yahoo.comAlkermes plc $ALKS is Affinity Asset Advisors LLC's 5th Largest PositionAugust 28, 2025 | marketbeat.comMetLife Investment Management LLC Boosts Stock Position in Alkermes plc $ALKSAugust 27, 2025 | marketbeat.com75,069 Shares in Alkermes plc $ALKS Purchased by Campbell & CO Investment Adviser LLCAugust 27, 2025 | marketbeat.comAlkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025August 25, 2025 | prnewswire.comPrice T Rowe Associates Inc. MD Sells 468,202 Shares of Alkermes plc $ALKSAugust 25, 2025 | marketbeat.comWhat is Zacks Research's Forecast for Alkermes Q3 Earnings?August 24, 2025 | marketbeat.com Get Alkermes News Delivered to You Automatically Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALKS Media Mentions By Week ALKS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALKS News Sentiment▼0.550.92▲Average Medical News Sentiment ALKS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALKS Articles This Week▼289▲ALKS Articles Average Week Get the Latest News and Ratings for ALKS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Alkermes and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Abeona Therapeutics News Medpace News Omnicell News AMN Healthcare Services News United Therapeutics News Incyte News Neurocrine Biosciences News BioMarin Pharmaceutical News Exact Sciences News Exelixis News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALKS) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALKS Stock Alerts